CEO of Arrowhead Pharmaceuticals Inc (30-Year Financial, Insider Trades) Christopher Richard Anzalone (insider trades) sold 100,000 shares of ARWR on 06/25/2020 at an average price of $38.81 a share. The total sale was $3.9 million.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins. Arrowhead Pharmaceuticals Inc has a market cap of $4.4 billion; its shares were traded at around $43.27 with a P/E ratio of 480.78 and P/S ratio of 31.01. GuruFocus has detected 1 severe warning sign with Arrowhead Pharmaceuticals Inc. .
CEO Recent Trades:
- CEO Christopher Richard Anzalone sold 100,000 shares of ARWR stock on 06/25/2020 at the average price of $38.81. The price of the stock has increased by 11.49% since.
Directors and Officers Recent Trades:
- Director Backer Marianne De bought 4,000 shares of ARWR stock on 06/15/2020 at the average price of $33.56. The price of the stock has increased by 28.93% since.
For the complete insider trading history of ARWR, click here
.
